C/EBPα is also a key transcription factor that regulates myeloid differentiation and modulates the expression of C/EBPα, causing resistance to imatinib, and is essential for chronic granulocytic leukemia treatment [20]. The gene discussed is CEBPA; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.